Is selinesol tablets included in medical insurance?

The trade name of Selinexor (Selinexor) is Xivio or Xpovio. The original drug has been approved by the National Medical Products Administration and has been marketed in China. It has also been included in the reimbursement of Class B medical insurance through the relevant regulations of the National Medical Insurance Bureau, and is sold under the name of Selenixor Tablets. When purchasing drugs at local hospitals or pharmacies, patients who meet the relevant indications can use their medical insurance to purchase them.

Selinesol, as an innovative drug, is mainly used to treat patients with specific types of multiple myeloma, that is, adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have previously received treatment and are refractory to at least one proteasome inhibitor, one immunomodulator, and one anti-CD38 monoclonal antibody. The inclusion of this indication reflects the medical insurance policy’s concern and support for meeting the clinical needs of patients.

From the perspective of drug properties, selinesol inhibits the function ofXPO1 (nuclear export protein 1), causing tumor suppressor proteins (TSPs) to accumulate in the nucleus, thereby reducing the expression of oncoproteins such as c-myc and cyclinD1, achieving cell cycle arrest and inducing apoptosis of cancer cells. This mechanism provides a new way to treat multiple myeloma and has demonstrated good efficacy and safety in clinical trials.

In terms of safety, the use of selinesol may be associated with some adverse reactions, such as thrombocytopenia, anemia, pneumonia, fatigue, etc. However, most of these adverse effects are reversible and can be alleviated with supportive care. Therefore, when using selinesol, patients should strictly follow their doctor's medication instructions and closely monitor their physical condition during treatment.